Latest Myocet Stories
QUEBEC CITY, June 2, 2014 /PRNewswire/ - Aeterna Zentaris Inc.
LAGUNA HILLS, Calif., April 17, 2014 /PRNewswire/ -- NanoSmart(®) and NanoValent, private pharmaceutical companies developing novel cancer pharmaceuticals, have entered into a research collaboration
A remarkable 98.7 percent of certain lower-risk breast cancer patients were cancer free for at least three years after taking a combination of the drugs Herceptin and Taxol.
A recent FDA-approved combination of therapies used to target HER2-positive breast cancer does not lead to increased cardiac problems for patients, but doctors should regularly perform cardiac